Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 1, 2009, Pages 32-36

  Ronquist, Gunnar ^a   Frithz, Göran ^b   Wang, Yu Hui ^b   Lindeborg, Torsten ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Malar Hospital   (Sweden)

Author keywords

Biopsy; Captopril; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Recurrence

Indexed keywords

CAPTOPRIL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; SURGEON; TUMOR BIOPSY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 61649092635     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590802468875     Document Type: Article

References (30)

1. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872-6.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsch PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
3. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-8.
4. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004;58:50-6.
5. Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 2004;23:317-29.
6. Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta 1985;822:203-18.
7. Sahlén G, Ahlander A, Frost A, Ronquist G, Norlén BJ, Nilsson BO. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004;61:291-7.
8. Ronquist G, Nilsson BO. The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 2004;7:21-31.
9. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005;173:777-80.
10. Ronquist G, Nilsson BO, Hjertén S. Interaction between prostasomes and spermatozoa from human semen. Arch Androl 1990;24:147-57.
11. Fabiani R, Johansson L, Lundkvist O, Ronquist G. Enhanced recruitment of motile spermatozoa by prostasome inclusion in swim-up medium. Hum Reprod 1994;9:1485-9.
12. Skibinski G, Kelly RW, Harkiss D, James K. Immunosuppression by human seminal plasma-extracellular organelles (prostasomes) modulate activity of phagocytic cells. Am J Reprod Immunol 1992;28:97-103.
13. Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 1995;177:1409-20.
14. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-5.
15. Folkman J, Watson K, Ingber D, Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
16. Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II induces proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990;8:565-72.
17. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.
18. Lyall F, Dornan ES, McQueen J, Boswell F, Kelly M. Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT 1 receptor. J Hypertens 1992;10:1463-9.
19. Krassnigg F, Niederhauser H, Fink E, Frick J, Schill WB. Angiotensin convertin enzyme in human seminal plasma is synthesized by the testis, epididymis and prostate. Int J Androl 1989;12:22-8.
20. Zucker S, Cao J. Detection of activated, TIMP-free MMPs. Chem Biol 13:347-9.
21. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 2006;274:21491-4.
22. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354:91-9.
23. Bellezza I, Aisa MC, Palazzo R, Costanzi E, Mearini E, Minelli A. Extracellular matrix degrading enzymes at the prostasome surface. Prostate Cancer Prostatic Dis 2005;8:344-8.
24. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-7.
25. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31:443-7.
26. Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Nilsson Ekdahl, K. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007;67:378-88.
27. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996;75:389-92.
28. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-9.
29. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000;86:139-43.
30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006;176:1404-8.